Renal cell carcinoma — an immunogenic tumor where personalized neoantigen vaccines are being evaluated in the adjuvant setting.
A Phase I trial of a neoantigen vaccine to treat advanced kidney cancer at Dana-Farber Cancer Institute showed all patients remained cancer free at a median of 35 months follow up. As reported in Nature, the vaccine was personalized to the nine patients in the trial depending on …
Peking University First Hospital is launching a Phase I investigator-initiated trial to evaluate a personalized neoantigen polyepitope peptide vaccine combined with pembrolizumab in advanced renal cell carcinoma. The study aims to enroll 5-8 patients across safety and expansion cohorts to address the high rate of primary or acquired resistance to pembrolizumab monotherapy.